» Articles » PMID: 23188748

Pharmacogenomics Discovery and Implementation in Genome-wide Association Studies Era

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical response to therapeutic treatments often varies among individual patients, ranging from beneficial effect to even fatal adverse reaction. Pharmacogenomics holds the promise of personalized medicine through elucidating genetic determinants responsible for pharmacological outcomes (e.g., cytotoxicities to anticancer drugs) and therefore guide the prescription decision prior to drug treatment. Besides traditional candidate gene-based approaches, technical advances have begun to allow application of whole-genome approaches to pharmacogenomic discovery. In particular, comprehensive understanding of human genetic variation provides the basis for applying GWAS (genome-wide association studies) in pharmacogenomic research to identify genomic loci associated with pharmacological phenotypes (e.g., individual dose requirement for warfarin). We therefore briefly reviewed the background for pharmacogenetic/pharmacogenomic research with statins and warfarin as examples for the GWAS discovery and their clinical implementation. In conclusion, with some challenges, whole-genome approaches such as GWAS have allowed unprecedented progress in identifying genetic variants associated with pharmacological phenotypes, as well as provided foundation for the next wave of pharmacogenomic discovery utilizing sequencing-based approaches. Furthermore, investigation of the complex interactions among genetic and epigenetic factors on the whole-genome scale will become the post-GWAS research focus for pharmacologic complex traits.

Citing Articles

Overnutrition and Lipotoxicity: Impaired Efferocytosis and Chronic Inflammation as Precursors to Multifaceted Disease Pathogenesis.

Mann V, Sundaresan A, Shishodia S Biology (Basel). 2024; 13(4).

PMID: 38666853 PMC: 11048223. DOI: 10.3390/biology13040241.


Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gomez-Cebrian N, Vazquez Ferreiro P, Carrera Hueso F, Poveda Andres J, Puchades-Carrasco L, Pineda-Lucena A Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681239 PMC: 8539252. DOI: 10.3390/ph14101015.


The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review.

Ortolan A, Cozzi G, Lorenzin M, Galozzi P, Doria A, Ramonda R Front Genet. 2021; 12:703911.

PMID: 34354741 PMC: 8329488. DOI: 10.3389/fgene.2021.703911.


Association between VKORC1 gene polymorphism and warfarin dose requirement and frequency of VKORC1 gene polymorphism in patients from Kerman province.

Soltani Banavandi M, Satarzadeh N Pharmacogenomics J. 2020; 20(4):574-578.

PMID: 31902949 DOI: 10.1038/s41397-019-0146-5.


Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines.

Ivanova M, Changsila E, Turgut A, Goker-Alpan O Am J Transl Res. 2019; 10(11):3750-3761.

PMID: 30662625 PMC: 6291725.


References
1.
Manolio T, Green E . Genomics reaches the clinic: from basic discoveries to clinical impact. Cell. 2011; 147(1):14-6. DOI: 10.1016/j.cell.2011.09.012. View

2.
Zhou K, Bellenguez C, Spencer C, Bennett A, Coleman R, Tavendale R . Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2010; 43(2):117-20. PMC: 3030919. DOI: 10.1038/ng.735. View

3.
Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F . SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008; 359(8):789-99. DOI: 10.1056/NEJMoa0801936. View

4.
Klein T, Altman R, Eriksson N, Gage B, Kimmel S, Lee M . Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360(8):753-64. PMC: 2722908. DOI: 10.1056/NEJMoa0809329. View

5.
Volpi S, Heaton C, Mack K, Hamilton J, Lannan R, Wolfgang C . Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2008; 14(11):1024-31. DOI: 10.1038/mp.2008.52. View